logo
Plus   Neg
Share
Email

Merck: FDA Approves KEYTRUDA-Inlyta Combination - Quick Facts

Merck (MRK) announced the U.S. FDA has approved KEYTRUDA in combination with Inlyta for the first-line treatment of patients with advanced renal cell carcinoma. Inlyta (axitinib) is a tyrosine kinase inhibitor.

The approval was based on data from the pre-specified interim analysis of a phase 3 KEYNOTE-426 trial, where KEYTRUDA-axitinib combination reduced the risk of death by nearly half compared to Sunitinib. The KEYNOTE-426 trial also showed significant improvements in overall survival, progression-free survival and objective response rate for the KEYTRUDA-axitinib combination compared to sunitini.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lawyers for the state of Oklahoma urged a judge on Monday to hold Johnson & Johnson (JNJ) responsible for the country's opioid epidemic. Oklahoma Attorney General Mike Hunter, in his closing arguments of the eight-week trial in Cleveland County, called the pharmaceutical company the "Kingpin" behind... Pizza chain Blaze Pizza has announced plans to offer a keto-diet-approved pizza crust, which will only have 6 grams of carbs. The pizza chain will swap flour for ingredients like flaxseeds, eggs, and cheese to offer the first-ever official keto-diet approved pizza. "As the first national chain... Even as Amazon.com Inc. kicked off its Prime Day annual shopping event on Monday, employees are expressing their dissatisfaction with the company. This year's Prime Day, Amazon's biggest celebration of deals, kick-started officially on Monday with more than one million offers for Prime Members in select countries around the world. The 48-hour extravaganza is the longest Prime Day ever.
Follow RTT